Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection

Journal of the European Academy of Dermatology and Venereology

Volumn 25, Issue 3, 2011, Pages 264-270

  Rutkowski, P ^a   Debiec Rychter M ^b   Nowecki, Z I ^a   Michej, W ^a   Symonides, M ^a   Ptaszynski, K ^a   Ruka, W ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

dermatofibrosarcoma protuberans; imatinib; outcomes; surgery

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 1A1; HYBRID PROTEIN; IMATINIB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CHROMOSOME TRANSLOCATION 17; CHROMOSOME TRANSLOCATION 22; CLINICAL ARTICLE; DERMATOFIBROSARCOMA PROTUBERANS; DIARRHEA; DRUG DOSE REDUCTION; EDEMA; EXCISION; FATIGUE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HISTOPATHOLOGY; HUMAN; KAPLAN MEIER METHOD; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SKIN TOXICITY; SOFT TISSUE METASTASIS; THROMBOCYTOPENIA; VOMITING;

ANTINEOPLASTIC AGENTS; CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, PAIR 22; COLLAGEN TYPE I; COMBINED MODALITY THERAPY; DERMATOFIBROSARCOMA; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-SIS; PYRIMIDINES; RETROSPECTIVE STUDIES; SARCOMA; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 79751475654     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2010.03774.x     Document Type: Article

References (56)

1. Laskin WB,. Dermatofibrosarcoma protuberans. CA Cancer J Clin 1992; 42: 116-125.
2. Mendenhall WM, Zlotecki RA, Scarborough MT,. Dermatofibrosarcoma protuberans. Cancer 2004; 101: 2503-2508. (Pubitemid 39532278)
3. Chang CK, Jacobs IA, Salti GI,. Outcomes of surgery for dermatofibrosarcoma protuberans. Eur J Surg Oncol 2004; 30: 341-345. (Pubitemid 38425655)
4. Mentzel T, Beham A, Katenkamp D, et al. Fibrosarcomatous 'high-grade' dermatofibrosarcoma protuberans: clinicopathological and immunohistochemical study of 41 cases with emphasis on prognostic significance. Am J Surg Pathol 1998; 22: 576-587. (Pubitemid 28213745)
5. Bowne WB, Antonescu CR, Leung DHY, et al. Dermatofibrosarcoma protuberans. A clinicopathological analysis of patients treated and followed at a single institution. Cancer 2000; 88: 2711-2720. (Pubitemid 30417931)
6. Lal P, Sharma R, Mohan H, Sekhon MS,. Dermatofibrosarcoma protuberans metastasizing to lymph nodes: a case report and review of literature. J Surg Oncol 1999; 72: 178-180.
7. Kimmel Z, Ratner D, Kim JYS, Wayne JD, Rademaker AW, Alam M,. Peripheral excision margins for dermatofibrosarcoma protuberans: a meta-analysis of spatial data. Ann Surg Oncol 2007; 14: 2113-2120. (Pubitemid 46988248)
8. Snow SN, Gordon EM, Larson PO, et al. Dermatofibrosarcoma protuberans: a report on 29 patients treated by Mohs micrographic surgery with long term follow-up and review of the literature. Cancer 2004; 101: 28-38. (Pubitemid 38812420)
9. Monnier D, Vidal C, Martin L, et al. Dermatofibrosarcoma protuberans: a population-based cancer registry descriptive study of 66 consecutive cases diagnosed between 1982 and 2002. J Eur Acad Dermatol Venereol 2006; 20: 1237-1242. (Pubitemid 44614621)
10. Gloster HM Jr, Harris KR, Roenigk RK,. A comparison between Mohs micrographic surgery and a wide surgical excision for the treatment of dermatofibrosarcoma protuberans. J Am Acad Dermatol 1996; 35: 82-87. (Pubitemid 26231329)
11. Gentele H,. Malignant, fibroblastic tumors of the skin: clinical and pathological-anatomical studies of 129 cases of malignant, fibroblastic tumors from cutaneous and subcutaneous layers observed at Radiumhemmet during period 1927-1947. Acta Derm Venereol Suppl (Stockh) 1951; 27: 1-180.
12. Roses DF, Valensi Q, LaTrenta G, et al. Surgical treatment of dermatofibrosarcoma protuberans. Surg Gynecol Obstet 1986; 162: 449-452. (Pubitemid 16026861)
13. Barnes L, Coleman JA Jr, Johnson JT,. Dermatofibrosarcoma protuberans of the head and neck. Arch Otolaryngol 1984; 110: 398-404. (Pubitemid 14109491)
14. Rutgers EJ, Kroon BB, Albus-Lutter CE, et al. Dermatofibrosarcoma protuberans: treatment and prognosis. Eur J Surg Oncol 1992; 18: 241-248.
15. Mark RJ, Bailet JW, Tran LM, et al. Dermatofibrosarcoma protuberans of the head and neck: report of 16 cases. Arch Otolaryngol Head Neck Surg 1993; 119: 891-896. (Pubitemid 23232299)
16. Koh CK, Ho CB, Bury HPR, et al. Dermatofibrosarcoma protuberans. Int J Dermatol 1995; 34: 256-260.
17. Stojadinovic A, Karpoff HM, Antonescu CR, et al. Dermatofibrosarcoma protuberans of the head and neck. Ann Surg Oncol 2000; 7: 696-704.
18. Ratner D, Thomas CO, Johnson TM, et al. Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans. Results of a multiinstitutional series with analysis of the extent of microscopic spread. J Am Acad Dermatol 1997; 37: 600-613. (Pubitemid 27446732)
19. Wacker J, Khan-Durani B, Hartschuh W,. Modified Mohs micrographic surgery in the therapy of dermatofibrosarcoma protuberans: analysis of 22 patients. Ann Surg Oncol 2004; 11: 438-444. (Pubitemid 40486756)
20. Dawes KW, Hanke CW,. Dermatofibrosarcoma protuberans treated with Mohs micrographic surgery: cure rates and surgical margins. Dermatol Surg 1996; 22: 530-534. (Pubitemid 26200108)
21. Khatri VP, Galante JM, Bold RJ, Schneider PD, Ramsamooj R, Goodnight JE,. Dermatofibrosarcoma protuberans: reappraisal of wide local excision and impact of inadequate initial treatment. Ann Surg Oncol 2003; 10: 1118-1122. (Pubitemid 40486838)
22. Suit H, Spiro I, Mankin HJ, Efird J, Rosenberg AE,. Radiation in management of patients with dermatofibrosarcoma protuberans. J Clin Oncol 1996; 14: 2365-2369. (Pubitemid 26264889)
23. Ballo MT, Zagars GK, Pisters P, Pollack A,. The role of radiation therapy in the management of dermatofibrosarcoma protuberans. Int J Radiat Oncol Biol Phys 1998; 40: 823-827. (Pubitemid 28150799)
24. Haas RL, Keus RB, Loftus BM, et al. The role of radiotherapy in the local management of dermatofibrosarcoma protuberans. Soft tissue tumors working group. Eur J Cancer 1997; 33: 1055-1060. (Pubitemid 27310781)
25. Buchdunger E, Ciotfi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295: 139-145.
26. Mol CD, Dougan DR, Schneider TR, et al. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem 2004; 279: 31655-31663. (Pubitemid 39037836)
27. Tuveson DA, Willis NA, Jacks T, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 2001; 20: 5054-5058. (Pubitemid 32769795)
28. Buchdunger E, Zimmermann J, Mett H,. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc Natl Acad Sci USA 1995; 92: 2558-2562.
29. McArthur GA, Demetri GD, van Oosterom A, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: imatinib target exploration consortium study B2225. J Clin Oncol 2005; 23: 866-873. (Pubitemid 46224187)
30. Schuetze S, Rutkowski P, Van Glabbeke MM, et al. Combined analysis of two phase II trials of imatinib in advanced dermatofibrosarcoma protuberans (DFSP). J Clin Oncol 2009; 27 (15 Suppl.): abstr 10520.
31. Pédeutour F, Simon MP, Minoletti F, et al. Translocation, t(17;22)(q22;q13), in dermatofibrosarcoma protuberans: a new tumor-associated chromosome rearrangement. Cytogenet Cell Genet 1996; 72: 171-174. (Pubitemid 26080105)
32. Simon M-P, Pedeutour F, Sirvent N, et al. Deregulation of the platelet-derived growth factor B-chain gene (PDGBF) via its fusion with the collagen gene (COL1A1) in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat Genet 1997; 15: 95-98. (Pubitemid 27014958)
33. Shimizu A, O'Brien KP, Sjöblom T, et al. The dermatofibrosarcoma protuberans-associated collagen type I-1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGFBB. Cancer Res 1999; 59: 3719-3723.
34. Simon M-P, Navarro M, Roux D, Terrier-Lacombe M-J, Coindre J-M, Pouysségur J,. Transforming properties of chimerical protein COL1A1-PDGFB generated by dermatofibrosarcoma protuberans-associated translocation t(17;22)(q22;q13.1). Cancer Genet Cytogenet 2001; 128: 82.
35. Sandberg AA, Bridge JA,. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: dermatofibrosarcoma protuberans and giant cell fibroblastoma. Cancer Genet Cytogenet 2003; 140: 1-12. (Pubitemid 36110633)
36. Kerob D, Pedetour F, Leboeuf C, et al. Value of cytogenetic analysis in the treatment of dermatofibrosarcoma protuberans. J Clin Oncol 2008; 26: 1757-1759.
37. Wang J, Morimitsu Y, Okamoto S, et al. COL1A1-PDGFB fusion transcripts in fibrosarcoma areas of six dermatofibrosarcomas protuberans. J Mol Diagn 2000; 2: 47-52.
38. Patel KU, Szabo SS, Hernandez VS, et al. Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion is identified in virtually all dermatofibrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcription polymerase chain reaction and fluorescence in situ hybridization assays. Hum Pathol 2008; 39: 184-193.
39. Greco A, Roccato E, Miranda C, Cleris L, Formelli F, Pierotti MA,. Growth-inhibitory effect of STI571 on cells transformed by the COL1A1/PDGF-beta rearrangement. Int J Cancer 2001; 92: 354-360. (Pubitemid 32249711)
40. Sjoblom T, Shimizu A, O'Brien KP, et al. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 2001; 61: 5778-5783. (Pubitemid 32769094)
41. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. JNCI 2000; 92: 205-216. (Pubitemid 30099779)
42. Maki RG, Awan RA, Dixon RH, Jhanwar S, Antonescu CR,. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer 2002; 100: 623-626. (Pubitemid 34832970)
43. Rubin BP, Schuetze SM, Eary JF, et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 2002; 20: 3586-3591. (Pubitemid 34983217)
44. Ruka W, Falkowski S, Wudarska J, et al. The partial response of lung metastases arising from dermatofibrosarcoma after one month of imatinib therapy-a case report. Nowotwory-J Oncol 2003; 53: 165-168. (Pubitemid 36604183)
45. Labropoulos SV, Fletcher JA, Oliveira AM, Papadopoulos S, Razis ED,. Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate. Anticancer Drugs 2005; 16: 461-466. (Pubitemid 40434613)
46. Mizutani K, Tamada Y, Hara K, et al. Imatinib mesylate inhibits the growth of metastatic lung lesions in a patient with dermatofibrosarcoma protuberans. Br J Dermatol 2004; 151: 235-237. (Pubitemid 39061309)
47. Heinrich MC, Joensuu H, Demetri GD, et al. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res 2008; 14: 2717-2725.
48. Rutkowski P, Van Glabbeke M, Rankin CJ, et al. Imatinib mesylate in advanced dermatofibrosarcoma protuberans (DFSP): pooled analysis of two phase II clinical trials. J Clin Oncol 2010; 20: 1772-1779.
49. Ugurel S, Utikal J, Mohr P, et al. Imatinib in locally advanced dermatofibrosarcoma protuberans (DFSP): a phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). J Clin Oncol 2006. ASCO Annual Meeting Proceedings Part I. June 20, 2006; 24 (18 Suppl.): 9561.
50. Lebbe C, Kerob D, Porcher R, et al. Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicentric phase II study on 25 patients. J Clin Oncol 2007; 25 (18 Suppl.): 10032.
51. Goldblum JR, Reith JD, Weiss SW,. Sarcomas arising in dermatofibrosarcoma protuberans: a reappraisal of biologic behaviour in eighteen cases treated by wide local excision with extended follow up. Am J Surg Pathol 2000; 24: 1125-1130. (Pubitemid 30612834)
52. Abbott JJ, Oliveira AM, Nascimento AG,. The prognostic significance of fibrosarcomatous transformation in dermatofibrosarcoma protuberans. Am J Surg Pathol 2006; 30: 436-443. (Pubitemid 43740143)
53. Gronchi A, Stacchiotti S, Pedeutour F, et al. Response to imatinib mesylate (IM) in fibrosarcoma (FS) arising in dermatofibrosarcoma protuberans (DFSP). J Clin Oncol 2008; 26 (20 Suppl.): abstr 10593.
54. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. NEJM 2002; 347: 472-480. (Pubitemid 34879334)
55. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364: 1127-1134. (Pubitemid 39296599)
56. McArthur G,. Dermatofibrosarcoma protuberans: recent clinical progress. Ann Surg Oncol 2007; 14: 2876-2886. (Pubitemid 47460644)